Advanced Cell Technology, Inc. (ACTC.OB) Perseverance and Dedication Leads to New Highs
After announcing the Food and Drug Administration's approval to proceed with clinical trials using human embryonic stem cells to research a therapy for Stargardt’s Macular Dystrophy a couple weeks ago, shares of Advanced Cell Technology continue to run northbound. The news shot the stock price up from around 4 cents to approximately 8 cents in a matter of hours as traders jumped on the “momentum train” and investors rejoiced that the breakthrough they have been waiting for started showing true signs of becoming a reality. The news was followed a few days later by the Company filing an Investigational New…